VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
NCT ID: NCT03268057
Last Updated: 2022-05-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
62 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-10-05
Study Completion Date
2020-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2503 administered in combination with avelumab.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775
Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
PHASE2
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02944396
Non-Small Cell Lung Cancer
COMPLETED
PHASE1
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
NCT00003847
Lung Cancer
TERMINATED
PHASE2
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
NCT03472560
Non-Small Cell Lung Cancer
Urothelial Cancer
TERMINATED
PHASE2
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT02412371
Non-small Cell Lung Cancer Stage III
TERMINATED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase 1b/2 study, designed to evaluate the safety, tolerability, and efficacy of VX15/2503 in combination with avelumab in subjects diagnosed with advanced (stage IIIB/IV) NSCLC who have either progressed on first or second-line systemic anticancer therapy or who have declined treatment with first or second-line system anticancer therapy. The primary objective (Dose Escalation Phase) is to evaluate the safety and tolerability of ascending doses of VX15/2503 Q2W in combination with avelumab 10mg/kg Q2W. The second primary objective (Dose Expansion Phase) is to evaluate safety and tolerability of the recommended phase 2 dose of VX15/2503 administered in combination with 10 mg/kg avelumab Q2W. The secondary objectives include (Dose Expansion Phase), a preliminary estimate of efficacy using the following in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Objective Response (OR), Duration of Response (DoR) and Progression-Free Survival (PFS), as well as making a preliminary estimate of efficacy using the following in accordance with iRECIST, OR, DoR and PFS. Additional secondary objectives are to characterize the pharmacokinetics profile of VX15/2503 and avelumab administered Q2W in combination, evaluate the immunogenicity of VX15/2503 and avelumab administered Q2W and evaluate VX15/2503 and avelumab pharmacodynamics markers including but not limited to receptor occupancy. Exploratory objectives include identification of candidate biomarkers of activity and biomarkers that may predict response to treatment with combination therapy of VX15/2503 and avelumab.
Enrollment will involve approximately 62 individuals who are 18 years of age or older with advanced non-small cell lung cancer. The study will be divided into two phases, dose escalation with up to 18 Immunotherapy naive subjects and dose expansion with up to 50 subjects (up to 22 subjects that are Immunotherapy naive and up to 28 subjects that have failed on Immunotherapy). Subjects that are enrolled in the dose escalation phase may continue into the dose expansion phase, as long as there is no evidence of disease progression. The subjects entering the dose expansion phase from dose escalation, may have their dose increased to the recommend phase 2 dose, once it is determined. Any subjects that have evidence of disease progression will be taken off of treatment and will have a post treatment safety follow-up visit 10 weeks after last treatment. Subjects that have discontinued study drug will also continue to be followed every 3 months for survival, or lost to follow-up. It is estimated that the study will take approximately 33 months between first subject enrolled and last subject visit.
Enrollment will involve approximately 62 individuals who are 18 years of age or older with advanced non-small cell lung cancer. The study will be divided into two phases, dose escalation with up to 18 Immunotherapy naive subjects and dose expansion with up to 50 subjects (up to 22 subjects that are Immunotherapy naive and up to 28 subjects that have failed on Immunotherapy). Subjects that are enrolled in the dose escalation phase may continue into the dose expansion phase, as long as there is no evidence of disease progression. The subjects entering the dose expansion phase from dose escalation, may have their dose increased to the recommend phase 2 dose, once it is determined. Any subjects that have evidence of disease progression will be taken off of treatment and will have a post treatment safety follow-up visit 10 weeks after last treatment. Subjects that have discontinued study drug will also continue to be followed every 3 months for survival, or lost to follow-up. It is estimated that the study will take approximately 33 months between first subject enrolled and last subject visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Carcinoma, Non-Small-Cell Lung
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
A dose escalation phase based on the use of a 3 + 3 design and treament of up to 6 subjects in each of three VX15/2503 dose levels; a fixed dose of avelumab will be employed. Once the recommended phase two dose is determined, subjects will receive that dose of VX15/205 combined with avelumab moving forward.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VX15/2503 + avelumab
VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
Group Type
EXPERIMENTAL
VX15/2503 + avelumab
Intervention Type
DRUG
Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX15/2503 + avelumab
Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age \> 18 years.
2. Signed informed consent prior to the performance of any study-specific procedures, including fresh tumor biopsies.
3. Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects. Subjects in the Dose Escalation Phase must be immunotherapy naïve.
4. i. Subjects in the Dose Escalation Phase must have either progressed on or declined standard first-line therapy. Subjects with fewer than 3 lines of prior palliative systemic anti-cancer therapy are eligible.
ii. Subjects in the Dose Expansion Phase must have progressed on a minimum of 2 cycles of standard of care platinum-based chemotherapy with or without immunotherapy, standard of care immunotherapy without chemotherapy or must have declined standard of care first-line treatment options. Subjects with fewer than 3 lines of prior palliative systemic anti-cancer therapy are eligible.
5. Subjects previously treated with systemic adjuvant/neoadjuvant therapy, other than immunotherapy are also eligible for the Dose Escalation Phase. Subjects previously treated with standard of care systemic adjuvant/neoadjuvant therapy are also eligible for the Dose Expansion Phase.
6. Measureable disease as defined by the RECIST 1.1.
7. Availability of archival or fresh tumor specimen that is suitable for analysis. Acceptable samples must have been acquired using core needle biopsy or excisional biopsy. Samples that were acquired using fine needle aspiration are not acceptable.
8. Tumor lesion accessible for biopsy after the start of treatment. (Note: this lesion should be separate from measurable lesions that will be used for response assessment.)
9. ECOG performance status (PS) score 0-1.
10. Left ventricular ejection fraction \> 50%
11. Tumors lack activating epidermal growth factor receptor (EGFR) mutations, ROS-1, or ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS mutation or squamous cell histology)..
12. Has adequate bone marrow, renal and hepatic function based upon laboratory tests as follows:
* Absolute neutrophil count \> 1500/µL
* Platelet count \> 100 x 103/µL
* Hemoglobin \> 9 g/dL, transfusion permitted
* Total bilirubin \< 1.5 x upper limit of normal (ULN) (or \< 3 x ULN for subjects with Gilbert's syndrome)
* Creatinine clearance ≥ 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate calculation
* AST \< 2.5 x ULN (5.0 x ULN in the presence of liver metastasis)
* ALT \< 2.5 x ULN (5.0 x ULN in the presence of liver metastasis).
13. Highly effective contraception (i.e., methods with a failure rate of less than 1 % per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Protocol Appendix 9.3, or as stipulated in national or local guidelines. Highly effective contraception must be used for the duration of trial treatment, and at least for 60 days after stopping trial treatment or 6 months after stopping chemotherapy \[or per label\]. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).
2. Signed informed consent prior to the performance of any study-specific procedures, including fresh tumor biopsies.
3. Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects. Subjects in the Dose Escalation Phase must be immunotherapy naïve.
4. i. Subjects in the Dose Escalation Phase must have either progressed on or declined standard first-line therapy. Subjects with fewer than 3 lines of prior palliative systemic anti-cancer therapy are eligible.
ii. Subjects in the Dose Expansion Phase must have progressed on a minimum of 2 cycles of standard of care platinum-based chemotherapy with or without immunotherapy, standard of care immunotherapy without chemotherapy or must have declined standard of care first-line treatment options. Subjects with fewer than 3 lines of prior palliative systemic anti-cancer therapy are eligible.
5. Subjects previously treated with systemic adjuvant/neoadjuvant therapy, other than immunotherapy are also eligible for the Dose Escalation Phase. Subjects previously treated with standard of care systemic adjuvant/neoadjuvant therapy are also eligible for the Dose Expansion Phase.
6. Measureable disease as defined by the RECIST 1.1.
7. Availability of archival or fresh tumor specimen that is suitable for analysis. Acceptable samples must have been acquired using core needle biopsy or excisional biopsy. Samples that were acquired using fine needle aspiration are not acceptable.
8. Tumor lesion accessible for biopsy after the start of treatment. (Note: this lesion should be separate from measurable lesions that will be used for response assessment.)
9. ECOG performance status (PS) score 0-1.
10. Left ventricular ejection fraction \> 50%
11. Tumors lack activating epidermal growth factor receptor (EGFR) mutations, ROS-1, or ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS mutation or squamous cell histology)..
12. Has adequate bone marrow, renal and hepatic function based upon laboratory tests as follows:
* Absolute neutrophil count \> 1500/µL
* Platelet count \> 100 x 103/µL
* Hemoglobin \> 9 g/dL, transfusion permitted
* Total bilirubin \< 1.5 x upper limit of normal (ULN) (or \< 3 x ULN for subjects with Gilbert's syndrome)
* Creatinine clearance ≥ 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate calculation
* AST \< 2.5 x ULN (5.0 x ULN in the presence of liver metastasis)
* ALT \< 2.5 x ULN (5.0 x ULN in the presence of liver metastasis).
13. Highly effective contraception (i.e., methods with a failure rate of less than 1 % per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Protocol Appendix 9.3, or as stipulated in national or local guidelines. Highly effective contraception must be used for the duration of trial treatment, and at least for 60 days after stopping trial treatment or 6 months after stopping chemotherapy \[or per label\]. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).
Exclusion Criteria
1. Prior therapy with any antibody or drug targeting T-cell coregulatory proteins (immune checkpoints), such as PD-1, PD-L1, or cytotoxic T lymphocyte antigen-4 in the Dose Escalation Phase only.
2. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade \> 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are acceptable.
3. Concurrent anticancer treatment within 28 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy \[with the exception of palliative bone directed radiotherapy\]; immune therapy, or cytokine therapy, except for erythropoietin.
4. Major surgery within 28 days before the start of trial treatment (excluding prior diagnostic biopsy); or use of any investigational drug within 28 days before the start of trial treatment.
5. Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). Note: Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be ≤10 mg per day of prednisone or equivalent.
6. Previous malignant disease other than the target malignancy to be investigated in this trial within the last 5 years (with the exception of adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the subject was deemed to have been cured with no additional therapy required or anticipated to be required.
7. Rapidly progressive disease disease (i.e. disease progression before or at the time of first tumor assessment, 8 - 12 weeks after initiation of systemic anti-cancer therapy).
8. ECOG performance status score ≥ 2.
9. Women who are pregnant or breastfeeding.
10. History of pneumonitis or other interstitial lung disease
11. Active or history of any autoimmune disease including colitis and inflammatory bowel disease (subjects with diabetes Type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.
12. Vaccination within 4 weeks of the first dose of avelumab and while on study is prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines).
13. Significant acute or chronic infection including, among others: Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen positive and HBV core antibody positive with reflex to positive HBV DNA or HBV core antibody positive alone with reflex to positive HBV DNA or positive HCV antibody with reflex to positive HCV RNA).
14. Central nervous system malignancy, the known presence of untreated or symptomatic CNS metastases. Subjects with treated brain metastasis must be stable and off steroids and anti-convulsants for at least 1 month prior to the start of study treatment. Subjects with suspected brain metastases at Screening should have a CT/MRI of the brain prior to study entry.
15. A history of hypersensitivity to other humanized monoclonal antibodies.
16. Significant cardiovascular disease (New York Heart Association Class II or greater), myocardial infarction within the 6 months prior to study entry, unstable angina, or cerebral vascular accident / stroke (\< 6 months prior to enrollment), or serious uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected QT interval \[QTc\] prolongation of \>= 470ms and/or prior diagnosis of congenital long QT syndrome.
17. Legal incapacity or limited legal capacity.
18. Current alcohol or drug abuse.
19. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
20. Prior organ transplantation or allogeneic bone marrow transplantation.
21. Any uncontrolled medical condition (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment or confound interpretation of study assessments.
22. Inability to comply with visit schedule or other protocol requirements.
2. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade \> 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are acceptable.
3. Concurrent anticancer treatment within 28 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy \[with the exception of palliative bone directed radiotherapy\]; immune therapy, or cytokine therapy, except for erythropoietin.
4. Major surgery within 28 days before the start of trial treatment (excluding prior diagnostic biopsy); or use of any investigational drug within 28 days before the start of trial treatment.
5. Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). Note: Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be ≤10 mg per day of prednisone or equivalent.
6. Previous malignant disease other than the target malignancy to be investigated in this trial within the last 5 years (with the exception of adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the subject was deemed to have been cured with no additional therapy required or anticipated to be required.
7. Rapidly progressive disease disease (i.e. disease progression before or at the time of first tumor assessment, 8 - 12 weeks after initiation of systemic anti-cancer therapy).
8. ECOG performance status score ≥ 2.
9. Women who are pregnant or breastfeeding.
10. History of pneumonitis or other interstitial lung disease
11. Active or history of any autoimmune disease including colitis and inflammatory bowel disease (subjects with diabetes Type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.
12. Vaccination within 4 weeks of the first dose of avelumab and while on study is prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines).
13. Significant acute or chronic infection including, among others: Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen positive and HBV core antibody positive with reflex to positive HBV DNA or HBV core antibody positive alone with reflex to positive HBV DNA or positive HCV antibody with reflex to positive HCV RNA).
14. Central nervous system malignancy, the known presence of untreated or symptomatic CNS metastases. Subjects with treated brain metastasis must be stable and off steroids and anti-convulsants for at least 1 month prior to the start of study treatment. Subjects with suspected brain metastases at Screening should have a CT/MRI of the brain prior to study entry.
15. A history of hypersensitivity to other humanized monoclonal antibodies.
16. Significant cardiovascular disease (New York Heart Association Class II or greater), myocardial infarction within the 6 months prior to study entry, unstable angina, or cerebral vascular accident / stroke (\< 6 months prior to enrollment), or serious uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected QT interval \[QTc\] prolongation of \>= 470ms and/or prior diagnosis of congenital long QT syndrome.
17. Legal incapacity or limited legal capacity.
18. Current alcohol or drug abuse.
19. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
20. Prior organ transplantation or allogeneic bone marrow transplantation.
21. Any uncontrolled medical condition (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment or confound interpretation of study assessments.
22. Inability to comply with visit schedule or other protocol requirements.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany
INDUSTRY
Sponsor Role
collaborator
Vaccinex Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John E Leonard, PhD
Role: STUDY_DIRECTOR
Vaccinex Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands Oncology Group, PA
Fayetteville, Arkansas, United States
Site Status
University of California Los Angeles (UCLA)
Los Angeles, California, United States
Site Status
Mayo Clinic
Jacksonville, Florida, United States
Site Status
Moffitt Cancer Center
Tampa, Florida, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Washington University School of Medicine
St Louis, Missouri, United States
Site Status
Northwell Health Cancer Institute
Lake Success, New York, United States
Site Status
University of Rochester
Rochester, New York, United States
Site Status
Gabrail Cancer Center
Canton, Ohio, United States
Site Status
Providence Portland Medical Center
Portland, Oregon, United States
Site Status
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.
Reference Type
BACKGROUND
Evans EE, Jonason AS Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015 Jun;3(6):689-701. doi: 10.1158/2326-6066.CIR-14-0171. Epub 2015 Jan 22.
Reference Type
BACKGROUND
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
Reference Type
BACKGROUND
Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schroder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1;27(13):3630-3640. doi: 10.1158/1078-0432.CCR-20-4792. Epub 2021 Apr 5.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.ncbi.nlm.nih.gov/pubmed/26446947
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Antibody+Blockade+of+Semaphorin+4D+Promotes+Immune+Infiltration+into+Tumor+and+Enhances+Response+to+Other+Immunomodulatory+Therapies
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX15/2503-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
NCT00702572
TERMINATED
PHASE1
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
NCT02395172
COMPLETED
PHASE3
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
NCT07246863
RECRUITING
PHASE2
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
NCT04274907
TERMINATED
PHASE1
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
NCT03406715
TERMINATED
PHASE2
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
NCT00675597
COMPLETED
NA
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805
COMPLETED
PHASE3
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078
COMPLETED
PHASE1/PHASE2
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT03583086
COMPLETED
PHASE1/PHASE2
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
NCT00404703
TERMINATED
PHASE2
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
NCT02613507
COMPLETED
PHASE3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712
TERMINATED
PHASE3
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759
COMPLETED
PHASE2
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00970684
COMPLETED
PHASE2
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
NCT01560104
COMPLETED
PHASE2
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
NCT00741988
COMPLETED
PHASE2
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00026156
COMPLETED
PHASE2
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT03041181
TERMINATED
PHASE2
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00356122
COMPLETED
PHASE2
Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
RECRUITING
PHASE2
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
NCT00064012
COMPLETED
PHASE2
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577
TERMINATED
PHASE2
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
NCT01957007
COMPLETED
PHASE1
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
NCT02584634
TERMINATED
PHASE1/PHASE2
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
NCT03728361
ACTIVE_NOT_RECRUITING
PHASE2